Vital Therapies reported $72.77M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Biomarin Pharmaceutical BMRN:US USD 761.52M 141.71M
Dynavax Technologies DVAX:US USD 586.49M 337.4M
Insmed INSM:US USD 414.63M 1.44M
Intercept Pharmaceuticals ICPT:US USD 113.2M 55.18M
Mirati Therapeutics MRTX:US USD 173.53M 71.97M
Omeros OMER:US USD 145.53M 131.4M
Orasure Technologies OSUR:US USD 75.2M 9.05M
Quidel QDEL:US USD 212.2M 166.8M
Regulus Therapeutics RGLS:US USD 20.01M 15.1M
Revance Therapeutics RVNC:US USD 104.49M 35.07M
Ultragenyx Pharmaceutical RARE:US USD 391.65M 231.78M
United Therapeutics UTHR:US USD 966.8M 171.6M
Vital Therapies VTL:US USD 72.77M 15.31M